Literature DB >> 524316

The effect of ticlopidine on platelet function in normal volunteers and in patients with platelet hyperaggregability in vitro.

J B Knudsen, J Gormsen.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 524316     DOI: 10.1016/0049-3848(79)90210-x

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


× No keyword cloud information.
  10 in total

1.  P1,P4-dithio-P2,P3-monochloromethylene diadenosine 5',5'''-P1,P4-tetraphosphate: a novel antiplatelet agent.

Authors:  S W Chan; S J Gallo; B K Kim; M J Guo; G M Blackburn; P C Zamecnik
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

Review 2.  Ticlopidine. An updated review of its pharmacology and therapeutic use in platelet-dependent disorders.

Authors:  D McTavish; D Faulds; K L Goa
Journal:  Drugs       Date:  1990-08       Impact factor: 9.546

3.  Antiplatelet drugs and thrombosis prevention: ticlopidine in perspective.

Authors:  G de Gaetano; V Bertelé
Journal:  Agents Actions       Date:  1984-01

Review 4.  Ticlopidine. A review of its pharmacology, clinical efficacy and tolerability in the prevention of cerebral ischaemia and stroke.

Authors:  S Noble; K L Goa
Journal:  Drugs Aging       Date:  1996-03       Impact factor: 3.923

5.  Platelet inhibition with Ticlopidine in atherosclerotic intermittent claudication.

Authors:  A Aukland; R A Hurlow; A J George; J Stuart
Journal:  J Clin Pathol       Date:  1982-07       Impact factor: 3.411

6.  Single and multiple dose pharmacokinetics of ticlopidine in young and elderly subjects.

Authors:  J Shah; P Teitelbaum; B Molony; T Gabuzda; I Massey
Journal:  Br J Clin Pharmacol       Date:  1991-12       Impact factor: 4.335

Review 7.  Pharmacokinetic optimisation of the treatment of embolic disorders.

Authors:  D M Lutomski; M Bottorff; K Sangha
Journal:  Clin Pharmacokinet       Date:  1995-01       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics of antiplatelet agents used in the secondary prevention of stroke.

Authors:  Thomas Lenz; Amy Wilson
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 9.  Ticlopidine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states.

Authors:  E Saltiel; A Ward
Journal:  Drugs       Date:  1987-08       Impact factor: 9.546

10.  Functionally thrombasthenic state in normal platelets following the administration of ticlopidine.

Authors:  G Di Minno; A M Cerbone; P L Mattioli; S Turco; C Iovine; M Mancini
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.